OBIO Q1 Revenue Estimate: $918.71K, EPS Expected at -$0.43
Summary
This news provides the specific analyst consensus estimates for Orchestra BioMed's Q1 2026 financial performance, with revenue projected at $918.71K and an EPS loss of $0.43. This follows a Reuters report from May 1st that anticipated a significant financial downturn for the quarter. While these are estimates and not actual results, they offer concrete figures for traders to incorporate into their models and positioning ahead of the official earnings announcement on May 18th. The negative EPS estimate reinforces the anticipated downturn. Traders will now focus on the actual results and any forward guidance provided during the earnings call.
At the time of this announcement, OBIO was trading at $4.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $236.4M. The 52-week trading range was $2.20 to $5.42. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.